Marketed By
medicamen
Pack of
28 tablets in strip
Salt Composition
Enzalutamide
Storage
Keep in cold place
₹3811₹5298.75
28.08% Off
Tax: ₹457.32
1
Enzamed 40mg Tablet
Delivering To: —
Description
Enzamed 40mg Tablet is a target therapy based chemotherapeutic medication.It is used to treat Metastatic and Non-Metastatic castration-resistant Prostate Cancer. Enzamed 40mg Tablet contains Enzalutamide salt that works by inhibiting the androgen receptors.As a result, this medication inhibits male hormone driven cancer progression. This medication can only be purchased after a doctor's prescription.
Dosage And Administration
The typical prescribed dosage of Enzamed 40mg Tablet is 160mg daily. It means patient need to consume 4 tablets daily. This medicine is taken orally with the help of water. Avoid breaking, chewing, biting of capsules to maintain its integrity and efficacy. To know about exact dosage and treatment time, visit your doctor for consultation.
Mechanism Of Action
Enzamed 40mg Tablet contains Enzalutamide salt that works by inhibiting the androgen receptors. Androgen receptors are responsible for testosterone hormone production. Blocking of androgen receptor reduces the testosterone hormone that helps in cancer cell growth and proliferation.As a result, this medication inhibits male hormone driven cancer progression. This medication can only be purchased after a doctor's prescription.
Faqs
Yes,Enzamed 40mg Tablet is especially for men and not to be consumed by women.
Enzamed 40mg Tablet contains Enzalutamide salt.
Enzamed 40mg Tablet contains Enzalutamide salt that works by inhibiting the androgen receptors.Therefore, prevents androgen production. As a result, cancer cells die due to lack of nutrition provided by hormone.
Yes, Enzamed 40mg Tablet is a hormone therapy based medicine that targets the androgen (male hormones).
Enzamed 40mg Tablet is used to treat Metastatic and Non-Metastatic castration-resistant Prostate Cancer.
References
• Beer, T. M., Armstrong, A. J., Rathkopf, D. E., Loriot, Y., Sternberg, C. N., Higano, C. S., ... & Tombal, B. (2014). Enzalutamide in metastatic prostate cancer before chemotherapy. New England Journal of Medicine, 371(5), 424-433.
• Davis, I. D., Martin, A. J., Stockler, M. R., Begbie, S., Chi, K. N., Chowdhury, S., ... & Sweeney, C. J. (2019). Enzalutamide with standard first-line therapy in metastatic prostate cancer. New England Journal of Medicine, 381(2), 121-131.
• Claessens, F., Helsen, C., Prekovic, S., Van den Broeck, T., Spans, L., Van Poppel, H., & Joniau, S. (2014). Emerging mechanisms of enzalutamide resistance in prostate cancer. Nature reviews urology, 11(12), 712-716.
• Moreira, R. B., Debiasi, M., Maluf, F. C., Bellmunt, J., Fay, A. P., Choueiri, T. K., & Schutz, F. A. B. (2016). Differential side effects profile in mCRPC patients treated with abiraterone or enzalutamide: A meta-analysis of randomized controlled trials.
Ratings And Reviews
4.57/5
7 Ratings
5 Star
57.14%
4 Star
42.86%
3 Star
0.00%
2 Star
0.00%
1 Star
0.00%
a year ago
a year ago
View All Reviews
Related Products
MARKETER DETAILS
medicamen
DISCLAIMER
The contents of this website are for informative purposes only. They are not deliberated to be an alternative to any professional medical prescription and treatment. Seek the advice of a qualified health provider for questions regarding the medical condition. Do not ignore any professional medical advice because of something you have read on this website. This website offers links to other websites, thereby enabling you to go to the other website directly. Therefore, Magicine Pharma isn't responsible for the content of the links in the website or links in the linked websites. The links are provided to assist the visitors and are not approved by any professional health provider.